Investigational drug · Phase 2
CT041
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Cancer, Pancreatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "CT041"
First trial start
2020
Oct 23, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CT041", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CT041" as an intervention, largest first.
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionPivotal-lookingActive, not recruiting
CARsgen Therapeutics Co., Ltd.Industry
NCT04581473 · 192 participants (planned) · Start Oct 23, 2020 · Primary completion Oct 18, 2024
Drug: CT041 autologous CAR T-cell injection; Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody) · For: Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Hefei, China; Beijing, China; Fuzhou, China · 24 sites in all
Peking UniversityAcademic, hospital or other
NCT03874897 · 134 participants · Start Mar 26, 2019 · Primary completion Mar 20, 2021
Drug: CAR-CLDN18.2 T-Cells; PD-1 Monoclonal Antibody and 1 more · For: Advanced Solid Tumor
Sites: Beijing, China; Zhengzhou, China; Hangzhou, China
- Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive CancersActive, not recruiting
CARsgen Therapeutics Co., Ltd.Industry
NCT04404595 · 110 participants (planned) · Start Oct 23, 2020 · Primary completion Jun 1, 2025
Drug: CT041 · For: Gastric Cancer; Pancreatic Cancer
Sites: Duarte, California; Los Angeles, California; San Diego, California · 16 sites in all
- Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma PatientsNot yet recruiting
Peking UniversityAcademic, hospital or other
NCT06857786 · 48 participants (planned) · Start Mar 10, 2025 · Primary completion Jun 30, 2027
Drug: Drug: CT041 autologous CAR T-cell injection · For: Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Beijing, China; Nanjing, China · 3 sites in all
Beijing GoBroad HospitalAcademic, hospital or other
NCT07179484 · 20 participants (planned) · Start Oct 22, 2025 · Primary completion Sep 1, 2027
Drug: CT041 autologous CAR T-cell injection · For: Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
CARsgen Therapeutics Co., Ltd.Industry
NCT05911217 · 20 participants (planned) · Start Jul 11, 2023 · Primary completion Dec 31, 2026
Drug: CT041 autologous CAR T-cell injection · For: Pancreatic Cancer
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers.
Zeng L, Wei S, Chen N, et al. · Front Immunol 2026
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.
Ismail M, Al-Gizey N, Alabed Z, et al. · Pharmaceuticals (Basel) 2026
- Extracellular vesicle proteins monitor and interfere with CLDN18.2-targeted CAR-T cell and antibody therapies against gastrointestinal cancers.
Qi C, Ma M, Liang K, et al. · Nat Commun 2026
- Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies.
Carstens EJ, Takahashi K, Sakamoto N, et al. · Nat Commun 2025
- Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting.
Dave P, Beriwala V, Parikh C, et al. · Cureus 2025
- Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
Qi C, Liu C, Peng Z, et al. · Lancet 2025
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.